{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.7","upperLimit":"39.2","value":"26.7"},{"groupId":"OG001","lowerLimit":"18.3","upperLimit":"42.7","value":"29.7"}]}],"title":"100 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.7","upperLimit":"39.2","value":"26.7"},{"groupId":"OG001","lowerLimit":"18.3","upperLimit":"42.7","value":"29.7"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.7","upperLimit":"39.2","value":"26.7"},{"groupId":"OG001","lowerLimit":"18.3","upperLimit":"42.7","value":"29.7"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"BK viremia or viruria with clinical consequence requiring prolonged therapy and/or surgical intervention). A cumulative incidence will be computed along with a 90% CI.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days, 180 days, 365 days","title":"Cumulative Incidences of Viral Reactivations and Infections: Grade 2 BK Virus Infection","type":"SECONDARY","unitOfMeasure":"percentage of participants"}